ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO468

Albuminuria Is Associated with Higher Carotid Plaque Volume Quantified by Novel 3D Ultrasound in Type 1 Diabetes

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Authors

  • Ferreira-Divino, Luis Felipe, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
  • Poulsen, Christina Gjerlev, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
  • Rotbain Curovic, Viktor, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
  • Urbak, Laerke, Rigshospitalet, Copenhagen, Denmark
  • Rouet, Laurence, Philips Health Technology Innovation, Paris, France
  • Frimodt-Moller, Marie, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
  • Hansen, Tine, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
  • Eldrup, Nikolaj, Rigshospitalet, Copenhagen, Denmark
  • Sillesen, Henrik Hegaard, Rigshospitalet, Copenhagen, Denmark
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark
Background

Carotid atherosclerosis is associated with progression of kidney disease. Novel 3D ultrasound (3DUS) methods to quantify carotid plaque volume (CPV) may potentially provide more accurate information on carotid atherosclerosis compared to conventional ultrasound methods. We investigated the association between CPV and albuminuria in individuals with type 1 diabetes (T1D) and healthy controls.

Methods

Total CPV (tCPV) was quantified using a novel 3DUS transducer (XL14-3, Philips Healthcare) and calculated as the sum of CPV bilaterally. Individuals with T1D were stratified based on historic albuminuria: normal (30 <mg/g), moderately (30-299 mg/g), or severely increased (≥300 mg/g). tCPV was Ln-transformed in all analyses. Association between tCPV and albuminuria groups was analyzed using linear regression with healthy controls as reference and adjusted for age, sex, systolic blood pressure, smoking, eGFR and LDL-cholesterol. Analyses were repeated solely including the T1D individuals, with the normal albuminuria group as reference, further adjusted for HbA1c. Estimates per one standard deviation increase in Ln-tCPV with 95% confidence intervals are presented.

Results

A total of 120 individuals with T1D and 20 healthy controls were included, 48% were female and mean (±SD) age was 54±15 years. Of the individuals with T1D, 30 had normal, 45 moderately and 45 severely increased albuminuria. Median (IQR) tCPV in each group was: healthy controls 11.6 (6.0-41.6) mm3, normal 13.0 (1.4-60.9) mm3, moderately increased 29.2 (17.8-106.1) mm3, and severely increased 46.3 (10.6-117.5) mm3 albuminuria. Participants with moderately and severely increased albuminuria had higher tCPV compared to healthy controls after adjustment (0.42, CI [0.01-0.83], p=0.05) and (0.60, CI [0.13-1.06], p=0.01), respectively. Among T1D, individuals with moderately (0.38, CI [0.03-0.72], p=0.03) and severely increased (0.53, CI [0.13-0.94], p=0.01) albuminuria had higher tCPV than individuals with normal albuminuria.

Conclusion

Individuals with T1D and moderately or severely increased albuminuria had higher tCPV, measured with a novel 3DUS method, compared to individuals with normal albuminuria and healthy controls.